ulcerative colitis
NICE backtracks to approve Janssen’s Stelara in ulcerative colitis
April 28, 2020Manufacturing and Production, Research and Development Janssen, NICE, Stelara, ulcerative colitis
NICE has recommended Janssen’s Stelara (ustekinumab) for the treatment of moderately to severely active ulcerative colitis (UC), a move which …
Janssen’s ulcerative colitis medicine not recommended by NICE for use in adults
January 21, 2020Manufacturing and Production IBS, Irrated Bowels, NHS, NICE, bowel, ulcerative colitis
NICE has published draft guidance which does not recommend Stelara (ustekinumab) for treating moderately to severely active ulcerative colitis in …
Takeda’s Entyvio outperforms AbbVie’s Humira in moderate-to-severe ulcerative colitis
September 27, 2019Medical Communications, Research and Development AbbVie, Entyvio, Humira, Takeda, pharma, ulcerative colitis
Takeda has released strong new data for Entyvio (vedolizumab), showing that the gut-selective biologic outperformed AbbVie’s blockbuster anti-tumour necrosis factor-alpha …
Janssen’s Stelara becomes first European-approved biologic IL-12/IL-23 inhibitor for ulcerative colitis
September 5, 2019Sales and Marketing Europe, Janssen, Stelara, pharma, ulcerative colitis
Janssen has announced that its therapy Stelara (ustekinumab) hass secured a label expansion from the European Commission, approving the drug …
Takeda’s Entyvio beats Humira for remission in ulcerative colitis, exploratory data show
May 20, 2019Research and Development, Sales and Marketing AbbVie Humira, Entyvio, Takeda, pharma, ulcerative colitis
Takeda has unveiled exploratory data on its gut-selective biologic drug Entyvio (vedolizumab) at the 2019 Digestive Disease Week, demonstrating its …
Janssen’s ulcerative colitis treatment shows positive results in phase 3 trials
March 13, 2019Manufacturing and Production, Research and Development Jansenn, Stelara, phase 3 trials, ulcerative colitis
Janssen’s ulcerative colitis treatment, Stelara (ustekinumab subcutaneous) has shown positive results as maintenance therapy in phase 3 trials. The study …
Takeda’s subcutaneous vedolizumab proves efficacious in Phase III trial for Ulcerative Colitis
October 22, 2018Sales and Marketing Takeda, UC, biologic, phase III, results, ulcerative colitis, vedolizumab
Japanese pharma firm Takeda has announced that the gut-selective biologic vedolizumab when taken as a subcutaneous (SC) injection, proved efficacious …
Janssen’s Stelara shows promise across two dosages in ulcerative colitis
October 9, 2018Manufacturing and Production, Research and Development Janssen, Stelara, pharma, ulcerative colitis
Janssen’s biologic therapy Stelara (ustekinumab) has shown new efficacy in the treatment of moderate to severe ulcerative colitis in two …
MSD’s ulcerative colitis drug scores expanded indication in Europe
July 9, 2018Sales and Marketing Europe, MSD, pharma, ulcerative colitis
New Jersey-based multinational MSD have announced that the European Commission (EC) has approved Simponi (golimumab) for early dose optimisation in …
Takeda’s Entyvio secures Japanese approval in ulcerative colitis
July 2, 2018Sales and Marketing Entyvio, Japan, Takeda, pharma, ulcerative colitis
Takeda Pharmaceutical has announced that its monoclonal antibody, Entyvio (vedolizumab), has been approved for the treatment of patients with moderately …
Pfizer’s Xeljanz becomes first JAK inhibitor approved in US for active ulcerative colitis
May 31, 2018Sales and Marketing FDA, Pfizer, US, Xeljanz, pharma, ulcerative colitis
Pfizer has revealed that its Janus kinase (JAK) inhibitor Xeljanz (tofacitinib) has received FDA approval for the treatment of adult …
Gilead terminates Phase II/III study for ulcerative colitis antibody
September 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, ulcerative colitis
Gilead has put the brakes on a Phase II/III study of its anti-MMP9 antibody GS-5745 for the treatment of ulcerative …
Ulcerative colitis treatment Xeljanz records positive top-line results in Phase III trial
July 29, 2016Medical Communications, Research and Development Pfizer, Xeljanz, tofacitinib, ulcerative colitis
Pfizer has announced positive top-line results from oral clinical trials for tofacitinib in ulcerative colitis (Octave) sustain, the third Phase …
New Humira data shows improved quality of life in ulcerative colitis patients
June 23, 2016Research and Development AbbVie, Humira, data, ulcerative colitis
New data on Humira (adalimumab) has been presented at the British Society of Gastroenterology, demonstrating the drug’s efficacy and improvement …
Takeda presents long-term Entyvio data in CD and UC
March 21, 2016Manufacturing and Production, Research and Development Crohn's, Crohn's and Colitis, Entyvio, Takeda, ulcerative colitis
Japan’s Takeda has presented interim findings from the GEMINI Long-Term Safety (LTS) study of ulcerative colitis drug Entyvio (vedolizumab) at …
Latest content
